TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00005594
Drug: ISIS 2503
Normalized name: ISIS 2503
DrugBank: ISIS 2503 (DB16181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
Study: NCT03114995
Drug: Tirofiban
Normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01074216
Drug: vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
Study: NCT04344717
Drug: Apixaban single dose
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured
Study: NCT04344717
Drug: Apixaban steady-state
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban
Study: NCT01735851
Drug: Thoracic epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02819479
Drug: 25% Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Route of administration:~In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.
Study: NCT02757027
Drug: Intravenous Crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study: NCT02757027
Drug: Intravenous HES
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study: NCT03795597
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.
Study: NCT03795597
Drug: Busulfan IV
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.
Study: NCT03795597
Drug: Melphalan IV
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.
Study: NCT02819479
Drug: Low-dose Intra-arterial Bevacizumab
Normalized name: ethinyl estradiol
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Route of administration:~In this study, the second step of the treatment will be administering intra-arterial targeted bevacizumab into the appropriate cervical artery.
Study: NCT00224133
Drug: Silodosin
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 8 mg daily
Study: NCT00151008
Drug: Bexarotene/NBUVB vs placebo NBUVB
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02516579
Drug: Siklos
Normalized name: Siklos
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00374478
Drug: Scopolamine
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02631447
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
Study: NCT02631447
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
Study: NCT02667587
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02667587
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00681785
Drug: dalteparine (Fragmin)
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: transurethrals surgery with and without dalteparine
Study: NCT04463173
Drug: Anaprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose, oral administration 30 minutes after breakfast with high fat food.
Study: NCT04463173
Drug: Anaprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose, oral administration before breakfast.
Study: NCT00190411
Drug: celiprolol
Normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol
Study: NCT00190411
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated controls excluding betablockers
Study: NCT00893217
Drug: Betaseron (Interferon beta-1b, BAY86-5046)
Normalized name: interferon beta-1b Injection [Betaseron]
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mcg
Study: NCT00893217
Drug: Betaseron (Interferon beta-1b, BAY86-5046)
Normalized name: interferon beta-1b Injection [Betaseron]
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mcg
Study: NCT03466801
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone was taken for oral administration with dosage of 1mg/kg/d (maximum 60mg/d) by 8 weeks to start.Then reduced Gradually until the end of the experiment.
Study: NCT03466801
Drug: MP and CTX
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone(MP) was injected for 3 day(if weight \>60kg ,500mg/d\<60kg,300mg/d ), methylprednisolone was 0.4mg/kg/d for 27 day.Cyclophosphamide(CTX) orally was 100mg/ d for 1 month.And repeated for six months.
Study: NCT01747161
Drug: physiological water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL physiological water. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
Study: NCT02354768
Drug: Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)
Normalized name: loperamide hydrochloride Oral Tablet [Maalox Anti-Diarrheal]
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01824446
Drug: Radiolabeled SPD602 (FBS0701, SSP-004184)
Normalized name: Cercidium floridum ssp. floridum pollen
DrugBank: Parkinsonia florida pollen (DB11006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
Study: NCT03197779
Drug: BMS-962212
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous Infusion administration over 2 hours or 5 days
Study: NCT03197779
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00556387
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
Study: NCT00556387
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
Study: NCT00045513
Drug: 7-hydroxystaurosporine
Normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00045513
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03737474
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
Study: NCT02331251
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02331251
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02331251
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02331251
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02331251
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02331251
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01209143
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vismodegib was supplied in hard gelatin capsules.
Study: NCT01209143
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone was supplied in tablets.
Study: NCT00956748
Drug: Ciprodex
Normalized name: Ciprodex
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
Study: NCT01848951
Drug: TAP Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound. The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants (subcostal position x2 and lateral position x2)
Study: NCT00603720
Drug: L-NAME
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
Study: NCT00603720
Drug: L-Arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aids in nitric oxide production
Study: NCT00603720
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alpha agonist; 10 μg/kg/min infusion during PET study
Study: NCT03310567
Drug: Epacadostat + pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each patient would be administered epacadostat orally twice a day and pembroluzimab by infusion once in a cycle of 21 days
Study: NCT00379405
Drug: Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
Study: NCT00787943
Drug: Topical benzoyl peroxide 10.0% cream - Formulation 1
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Study: NCT00787943
Drug: Topical benzoyl peroxide 10.0% cream - Formulation 2
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Study: NCT00464685
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.
Study: NCT00464685
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial sham injection with up to 1 additional treatment based on re-treatment criteria.
Study: NCT02037061
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.
Study: NCT00729742
Drug: Comparator: erlotinib + dalotuzumab
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part II: All patients will receive 1 week of erlotinib 150 mg tablets per day.~Arm 1: Patients who experience a PET response will continue on erlotinib monotherapy until disease progression.~Arm 2: Patients who fail to receive a PET response will continue to take erlotinib in combination with dalotuzumab 10 mg/kg IV infusion once weekly. At the time of disease progression, patients on erlotinib monotherapy will be offered to crossover to dalotuzumab 10 mg/kg IV infusion once weekly in combination with erlotinib.
Study: NCT00729742
Drug: Comparator: erlotinib monotherapy
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part I: All patients will receive erlotinib 150 mg tablets per day until disease progression.
Study: NCT03625011
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively.
Study: NCT03604003
Drug: potassium losartan
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treated with bedtime or awakening doses of potassium losartan
Study: NCT03736473
Drug: MEDI9447 (oleclumab)
Normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI9447 administered intravenously
Study: NCT03500913
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
Study: NCT00810394
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
Study: NCT00096343
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00096343
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01225419
Drug: Plerixafor, mozobil
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection of 240 µg/kg of Plerixafor (Mozobil ®, Genzyme) at 8 am the day of the cytapheresis. Determination of CD34+ cells circulating in h0 then every hour of h3 to h11. Taking by cytapheresis from the 5th hour of the injection if the rate of CD34+ is upper or equal in 10.106/l. If the rate of CD34+ in the blood does not reach 10.106/l after the first injection of plerixafor or if the first cytapheresis does not allow the collection of at least 5.106/kg CD34+ cells, the patient will be considered in failure and a conventional mobilization by G-CSF will be programmed
Study: NCT00557466
Drug: indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
Study: NCT00557466
Drug: formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
Study: NCT00557466
Drug: placebo to indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo TWISTHALER® device
Study: NCT00557466
Drug: placebo to formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo AEROLIZER® device
Study: NCT00557466
Drug: short acting β2- agonist
Normalized name: sodium fluoride 0.2 MG/ML [ACT Fluoride Rinse]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
Study: NCT04912076
Drug: BM41
Normalized name: Beclomethasone
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of increasing doses of BM41
Study: NCT04912076
Drug: ALK Alutard SQ Betula verrucosa
Normalized name: Betula verrucosa tar oil
DrugBank: Betula pendula tar oil (DB11361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections with increasing doses of Alutard according to cluster up-dosing scheme.
Study: NCT03330119
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The regular Lankenau cesarean section order set includes routine vital signs, labs, IV fluids, and fetal heart monitoring. Post standard cesarean section orders include IV fluids running at 125 cc/ hour, along with routine post-partum care. In terms of pain control, most patients receive 9 doses of 30mg of IV ketorolac every 6 hours, along with hydromorphone, oxycodone/acetaminophen, or a hydromorphone PCA, per patient or attending request.
Study: NCT02593500
Drug: Budesonide 200 µg
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01857752
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01455493
Drug: GDC-0980
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral daily dose
Study: NCT02647918
Drug: Sotagliflozin
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Single dose
Study: NCT02647918
Drug: Sotagliflozin
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 2 single doses
Study: NCT03318744
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.
Study: NCT01548404
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection altered between back of arms, abdomen and upper thighs.
Study: NCT02654678
Drug: Enalapril Orodispersible Minitablet
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength
Study: NCT00350532
Drug: clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
Study: NCT00002331
Drug: Ethambutol hydrochloride
Normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002331
Drug: Clofazimine
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01313117
Drug: Alpha lipoic acid
Normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
Study: NCT03311854
Drug: Emapalumab
Normalized name: Emapalumab
DrugBank: Emapalumab (DB14724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emapalumab was administered at an initial dose of 6 mg/kg by intravenous infusion. Emapalumab treatment continued at a dose of 3 mg/kg, every 3 days until study day 15, and then twice-a-week for an additional 2 weeks, i.e., until study day 28. The emapalumab regimen could be adapted (the frequency between infusions shortened, the dose increased, or the treatment prolonged beyond 4 weeks) upon assessment of a favourable benefit-risk profile. There was a 4-week off-drug follow-up period (up to Week 8).
Study: NCT01294423
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
Study: NCT02396043
Drug: protocol M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56
Study: NCT02396043
Drug: Intrathecal (IT)
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
Study: NCT04461483
Drug: TAK-935
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-935 Tablets
Study: NCT01294423
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose